[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"geographic-atrophy-from-age-related-macular-degeneration\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:geographic-atrophy-from-age-related-macular-degeneration":77},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,3,0,[8,39,66],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":19,"enrollmentInfo":20,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":33,"leadSponsor":35,"locationsCount":38},"100641618","lesion-tailored-fundus-controlled-perimetry-in-geographic-atrophy-ga-100641618",false,"NCT07582042","Lesion-tailored, Fundus-controlled Perimetry in Geographic Atrophy (GA).","Integration of Lesion-tailored, Fundus-controlled Perimetry Into Routine Clinical Care for Patients With Geographic Atrophy (GA) Receiving Pegcetacoplan Treatment in Accordance With the Approved Label.","FCPGA-2025","Inclusion Criteria:\n\n* Age 65-90 years.\n* Geographic Atrophy (GA) secondary to dry Age-related Macular Degeneration (AMD) in at least one eye with the following criteria:\n\n  * GA lesion size between 1 and 15 mm² (≈ 0.4 to 6 disc areas)\n  * GA borders must be at least 500 μm from the edge of the 30° × 25° optical coherence tomography (OCT) image frame\n  * No confluent GA extending into peripapillary atrophy\n* Receiving intravitreal pegcetacoplan per label (at least one injection before screening).\n* Best-corrected visual acuity (BCVA) of 0.1 - 1.0 logMAR (≈ 20\u002F20 to 20\u002F200 Snellen)\n* Able to undergo mesopic FCP and required imaging.\n* Informed consent provided.\n\nExclusion Criteria:\n\n* Currently or previously active exudative macular neovascularization in the study eye.\n* High refractive errors (\\> ±5.00 Diopters \\[D\\] spherical equivalent) and significant astigmatism (\\> 2.50 D).\n* Ocular comorbidities likely to confound sensitivity or imaging (e.g., diabetic retinopathy with macular edema, retinal vein occlusion (RVO), inherited retinal disease, uncontrolled glaucoma).\n* Media opacity precluding reliable fundus-controlled perimetry (FCP) or imaging (e.g., dense cataract, corneal opacity, vitreous hemorrhage).\n* Any systemic condition judged likely to compromise participation, follow-up, or data integrity.","ALL","65 Years","90 Years",{"count":21,"type":22},50,"ESTIMATED","OBSERVATIONAL","The goal of this observational study is to evaluate changes in retinal sensitivity over time in patients with geographic atrophy due to age related macular degeneration who are receiving pegcetacoplan as part of routine clinical care. The study aims to determine whether lesion tailored fundus-controlled perimetry can reliably measure functional changes near areas of atrophy and whether this testing can be implemented in everyday clinic care over 24 months. Participants will undergo repeated vision testing, standard eye imaging, and visual function questionnaires while continuing their prescribed treatment.",[26],"Geographic Atrophy From Age-related Macular Degeneration","RECRUITING","2026-06-15",{"date":30,"type":31},"2026-06-17","ACTUAL",{"date":28,"type":31},{"date":34,"type":22},"2029-08-01",{"name":36,"class":37},"University of Utah","OTHER",1,{"id":40,"slug":41,"hasResults":11,"nctId":42,"briefTitle":43,"officialTitle":43,"acronym":44,"eligibilityCriteria":45,"healthyVolunteers":11,"sex":17,"minAge":46,"maxAge":4,"enrollmentInfo":47,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":49,"conditions":50,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":56,"lastUpdatePostDateStruct":57,"startDateStruct":59,"completionDateStruct":61,"leadSponsor":63,"locationsCount":38},"100631590","development-and-evaluation-of-functional-visual-field-and-navigation-endpoints-in-moderate-to-profound-inherited-retinal-disease-define-ird-100631590","NCT07502664","Development and Evaluation of Functional Visual Field and Navigation Endpoints in Moderate to Profound Inherited Retinal Disease (DEFINE-IRD)","DEFINE-IRD","Inclusion Criteria:\n\n* Diagnosis of bilateral retinitis pigmentosa (RP) or other retinal dystrophies impacting peripheral vision as confirmed from previous eye examination records\n* Best-corrected visual acuity between 20\u002F200 to HM in at least one eye.\n* Reasonably fluent in English or Spanish\n\nExclusion Criteria:\n\n* Cognitive impairment, memory loss or dementia sufficient in severity to preclude informed consent or in the opinion of the investigator would prevent satisfactory completion of some or all of the testing.\n* Any circumstance that in the opinion of the investigator, would interfere with participation in, or compliance with the study protocol\n* Current pregnancy as reported by patient","18 Years",{"count":48,"type":22},25,"The Vision Research and Assessment Institute (VRAI) was established with the purpose of serving as a testing facility for efficacy endpoints for patients with Low Vision.\n\nThe mission of the VRAI is to enable the highest quality, standardized efficacy testing of patients with visual impairment.\n\nThe VRAI facilitates the development and refinement of existing endpoints specifically for testing patients with Low Vision.",[51,52,53,26,54,55],"Retinitis Pigmentosa","Stargardt Macular Dystrophy","Stargardt Disease","X-linked Retinoschisis","Retinal Dystrophies","2026-03-24",{"date":58,"type":31},"2026-03-31",{"date":60,"type":31},"2026-02-19",{"date":62,"type":22},"2027-02",{"name":64,"class":65},"Ray Therapeutics, Inc.","INDUSTRY",{"id":67,"slug":68,"hasResults":11,"nctId":69,"briefTitle":70,"officialTitle":71,"acronym":4,"eligibilityCriteria":72,"healthyVolunteers":11,"sex":17,"minAge":46,"maxAge":4,"enrollmentInfo":73,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":49,"conditions":75,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":79,"lastUpdatePostDateStruct":80,"startDateStruct":82,"completionDateStruct":84,"leadSponsor":86,"locationsCount":38},"100544926","observational-study-to-assess-endpoint-operational-feasibility--measurement-properties-in-patients-with-retinal-degeneration-100544926","NCT06375239","Observational Study to Assess Endpoint Operational Feasibility & Measurement Properties in Patients with Retinal Degeneration","Observational, Non-Interventional Study to Determine the Operational Feasibility and Measurement Properties of Endpoints in Patients with Retinal Degeneration","Inclusion Criteria:\n\n* Diagnosis of bilateral retinitis pigmentosa, choroideremia, Stargardt macular dystrophy, geographic atrophy from age-related macular degeneration, X-linked retinoschisis or other retinal dystrophies confirmed from previous eye examination records\n* Best-corrected visual acuity between 20\u002F70 and HM in at least one eye as tested with clinic-based visual acuity method\n* Reasonably fluent in English\n\nExclusion Criteria:\n\n* Cognitive impairment, memory loss or dementia sufficient in severity to preclude informed consent or in the opinion of the investigator would prevent satisfactory completion of some or all of the testing.\n* Any circumstance that in the opinion of the investigator, would interfere with participation in, or compliance with the study protocol\n* Current pregnancy as reported by patient",{"count":74,"type":22},120,[51,76,52,53,77,78,55],"Choroideremia","Geographic Atrophy from Age-related Macular Degeneration","X-lined Retinoschisis","2025-01-06",{"date":81,"type":31},"2025-01-08",{"date":83,"type":31},"2024-04-05",{"date":85,"type":22},"2026-04-30",{"name":64,"class":65}]